Course of malignant pheochromocytoma. Clinical case
https://doi.org/10.62546/3034-1477-2024-2-3-53-61
Abstract
Pheochromocytomas (PH) are rare catecholamine-secreting neuroendocrine tumors, which are hereditary in almost 40% of cases. Symptoms of pheochromocytoma are caused by excessive production of catecholamines or mass effect. The frequency of metastasis of PH can reach 25%. Patients with pheochromocytoma have a 4-fold higher risk of developing other malignant neoplasms (in men, liver cancer, biliary tract cancer, and central nervous system tumors are mainly diagnosed).
This article discusses a case of primary multiple change pheochromocytoma and gastric cancer. The main objective of the article is to increase clinical alertness and relevance of the problems of differential diagnosis and treatment in the progression of pheochromocytoma after a long relapse-free period.
Supporting agencies: The article was prepared without sponsorship.
About the Author
M. M. Salnikova
Pskov Regional Oncology Dispensary
Russian Federation
Russian Federation
Salnikova Maria Mikhailovna
st. Vokzalnaya, 15a, Pskov, 180004
References
1. Rumyantsev P.O., Yazykova D.R., Slashchuk K.Yu., Degtyarev M.V., Yasyuchenya V.S., Serzhenko S.S., Sheremeta M.S., Dedov I.I. Personalized diagnosis of chromaffin tumors (pheochromocytoma, paraganglioma) in oncoendocrinology. Endocrine surgery, 2018, Vol. 12, No. 1, pp. 19–39 (In Russ.)
2. Neumann H.P., Bausch B., McWhinney S.R. et al. Germ-line mutations in nonsyndromic pheochromocytoma // N. Engl. J. Med. 2002. Vol. 346, No. 19. Р. 1459–1466. doi: 10.1056/NEJMoa020152.
3. Dahia P.L. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity // Nat. Rev. Cancer. 2014. Vol. 14, No. 2. Р. 108–119. doi: 10.1038/nrc3648.
4. Cascon A, Inglada-Perez L, Comino-Mendez I, et al. Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients // Endocr. Relat. Cancer. 2013. Vol. 20, No. 3. Р. L1–6. doi: 10.1530/ERC-12-0339.
5. Harari A., Inabnet W.B. Malignant pheochromocytoma: a review // The American Journal of Surgery. 2011. Vol. 201, No. 5. Р. 700–708. doi: 10.1016/j.amjsurg.2010.0
6. Kopetschke R., Slisko M., Kilisli A. et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma // Eur. J. Endocrinol. 2009. Vol. 161, No. 2. Р. 355–361. doi: 10.1530/EJE-09-0384.
7. Кiernan C.M., Solorzano C.C. Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment // Surg. Oncol. Clin. N. Am. 2016. Vol. 25. Р. 119–138.
8. Dahia P.L. Pheochromocytomas and paragangliomas, genetically diverse and minimalist, all at once! // Cancer Cell. 2017. Vol. 31. Р. 159–161.
9. Bravo E.L., Tagle R. Pheochromocytoma: state-of-the-art and future prospects // Endocr. Rev. 2003. Vol. 24, No. 4. Р. 539–553. doi: 10.1210/er.2002-0013
10. Falhammar H., Kjellman M., Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center // Endocr. Connect. 2018. Vol. 7, No. 1. Р. 186–192.
11. Baguet J.P., Hammer L., Mazzuco T.L. et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients // Eur. J. Endocrinol. 2004. Vol. 150, No. 5. Р. 681–686.
12. Falhammar H., Kjellman M., Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center // Endocrine. 2018. Vol. 62, No. 3. Р. 566–575.
13. Unger N., Deutschbein T., Walz M.K, Mann K., Petersenn S. The value of immunoassays for metanephrines in the biochemical diagnosis of pheochromocytomas // Horm. Metab. Res. 2009. Vol. 41, No. 9. Р. 676–679.
14. Van Berkel A., Lenders J.W., Timmers H.J. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma // Eur. J. Endocrinol. 2014. Vol. 170, No. 3. Р. R109-R119.
15. D’Herbomez M., Forzy G., Bauters C. et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas // Eur. J. Endocrinol. 2007. Vol. 156, No. 5. Р. 569–575.
16. Tufton N., White G., Drake W.M. et al. Diffusionweighted imaging (DWI) highlights SDHB-related tumours: a pilot study // Clin. Endocrinol. (Oxf). 2019. Vol. 91, No. 1. Р. 104–109.
17. Luster M., Karges W., Zeich K. et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma // Eur. J. Nucl. Med. Mol. Imaging. 2009. Vol. 37, No. 3. Р. 484–493. doi: 10.1007/s00259-009-1294-7.
18. Lenders J.W., Duh Q.Y., Eisenhofer G. et al.; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline // J. Clin. Endocrinol. Metab. 2014. Vol. 99, No. 6. Р. 1915–1942.
19. Lenders J.W.M., Kerstens M.N., Amar L. et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension // J. Hypertens. 2020. Vol. 38, No. 8. Р. 1443–1456.
20. Hamidi O., Young W.F. Jr, Iñiguez-Ariza N.M. et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years // J. Clin. Endocrinol. Metab. 2017. Vol. 102, No. 9. Р. 3296–3305.
21. Roman-Gonzalez A., Zhou S., Ayala-Ramirez M. et al. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma // Ann. Surg. 2018. Vol. 268, No. 1. Р. 172–178.
22. Khorram-Manesh A., Ahlman H., Nilsson O. еt al. Mortality associated with pheochromocytoma in a large Swedish cohort // Eur. J. Surg. Oncol. 2004. Vol. 30. Р. 556–559.
23. Lehnert H., Hahn K., Dralle H. [Benign and malignant pheochromocytoma] // Internist (Berl.). 2002. Vol. 43. Р. 196, 199–209.
24. Mei L. et al. Malignant Paraganglioma // Horm. Metab. Res. 2019. Vol. 51. Р. 451–457.
Review
For citations:
Salnikova M.M. Course of malignant pheochromocytoma. Clinical case. Clinical Case in Oncology. 2024;2(3):53-61. (In Russ.) https://doi.org/10.62546/3034-1477-2024-2-3-53-61
Views:
141
Email this article 